Document text
Principal Investigator: Kristen A Johnson
Organization: SCRIPPS RESEARCH INSTITUTE, THE
Fiscal Year: 2022
Award: $2,503,204
Funding agency: National Institute of Allergy and Infectious Diseases
SUMMARY
The emergence of SARS-CoV-2 into a worldwide pandemic has accounted for > 4,800,000 deaths worldwide,
has exposed the dearth of antiviral therapeutics needed to control, treat and prevent infections from viruses of
pandemic potential. Despite the successful development and deployment of multiple vaccines with high efficacy,
vaccine hesitancy and continued emergence of escape mutants have undermined disease control and placed
an urgent need for small-molecule medicines to supplement vaccines. Within this proposal, high throughput
target-based and cell-based screening approaches are being pursued to provide a comprehensive drug
discovery program to identify direct-acting antivirals. The Center for Antiviral Medicines and Pandemic
Preparedness (CAMPP) High-throughput Screening (HTS) Core (Core A) will coordinate and execute the
screening of Scripps Calibr’s >800,000 small molecule probe libraries which includes focused antiviral
collections, propriety fully functional fragment libraries, access to DNA-encoded libraries and chemically diverse,
small-molecule libraries. This will lead to the identification of validated screening hits and execution of hit follow-
up studies in coordination with the Medicinal Chemistry Core. Essential to the success of CAMPP is the HTS
core’s ability to support internal and external screening by managing small molecule probe libraries, screen data,
compound follow-up and medicinal chemistry support. The HTS Core has extensive experience with each of
those functions, managing > 352 internal and external screens in its nine years of existence. This includes a fully
established compound management team, scientists to complete initial assay optimization (or transfer from a
collaborator with antiviral expertise), developing miniaturized (384- and 1536-well) assays using fluorescent,
luminescence or high-content imaging readouts in addition to data analysis, storage and dissemination among
team members. The HTS Core also has a fully enabled BSL3 workflow to evaluate and characterize antiviral
activity against SARS-CoV-2 in high-throughput live virus assays. Together, the proposed CAMPP is comprised
of a collective team of scientists truly unmatched in non-profit drug discovery integrated with an industry-grade
high-throughput screening facility with world-leading structural biologists, virologists and chemists to develop
and apply innovative assays that recapitulate understudied aspects of the viral pathogenesis to identify and
development new therapeutic antiviral approaches.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Active Follow-up><Antiproteases><Antiviral Agents><Antiviral Drugs><Antivirals><Assay><Bioassay><Biochemical><Biologic Assays><Biological><Biological Assay><COVID-19 virus><COVID19 virus><Cell Body><Cells><Cessation of life><Chemical Structure><Chemicals><Chemistry><CoV-2><CoV2><Collection><Complex><DNA><Data><Data Analyses><Data Analysis><Data Store><Death><Deoxyribonucleic Acid><Deposit><Deposition><Derivation><Derivation procedure><Development><Endopeptidase Inhibitors><Ensure><Escape Mutant><Evaluation><Faculty><Follow-Up Studies><Followup Studies><Generations><Guidelines><HSV><Herpes Simplex Virus><Herpes labialis Virus><High Throughput Assay><Image><Industry><Infection><Infection prevention><Investigators><Lead><Libraries><Medicinal Chemistry><Medicine><Metadata><Modeling><Molecular Virology><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><Patients><Pb element><Peptidase Inhibitors><Peptide Hydrolase Inhibitors><Peptide Peptidohydrolase Inhibitors><Persons><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Polymerase><Pre-Clinical Model><Preclinical Models><Prevent infection><Protease Antagonists><Protease Inhibitor><Proteinase Inhibitors><Proteins><Reporting><Reproducibility><Research Personnel><Researchers><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 inhibitor><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Scientist><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 inhibitor><Severe acute respiratory syndrome related corona virus 2><Shipping><Simplexvirus><Structural Biologist><Structural Models><Supplementation><Technology><Time><Toxic effect><Toxicities><Translations><United States National Institutes of Health><Vaccines><Validation><Viral><Viral Burden><Viral Diseases><Viral Load><Viral Load result><Viral Pathogenesis><Virus><Virus Diseases><Wuhan coronavirus><active followup><analog><anti-viral agents><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><antiviral compound><antiviral medication><antiviral therapeutic><assay development><base><biologic><block SARS-CoV-2><block severe acute respiratory syndrome coronavirus 2><chemical library><clinical candidate><coronavirus disease 2019 virus><coronavirus disease-19 virus><data dissemination><data interpretation><data sharing><data standardization><data standards><depository><design><designing><developmental><disease control><disorder control><drug candidate><drug development><drug discovery><druggable target><effective therapy><effective treatment><experience><follow up><follow-up><followed up><followup><hCoV19><heavy metal Pb><heavy metal lead><hesitant to vaccination><high throughput screening><imaging><improved><in vitro activity><inhibit SARS-CoV-2><inhibit severe acute respiratory syndrome coronavirus 2><inhibitor><innovate><innovation><innovative><lead candidate><lead optimization><luminescence><member><meta data><miniaturize><nCoV2><new drug treatments><new drugs><new therapeutics><new therapy><next generation><next generation therapeutics><novel><novel drug treatments><novel drugs><novel therapeutics><novel therapy><pandemic><pandemic disease><pandemic preparedness><pathogen><pathogenic virus><pre-clinical><preclinical><preservation><programs><public repository><publicly accessible repository><publicly available repository><repository><screening><small molecule><small molecule libraries><success><vaccination hesitancy><vaccine hesitancy><vaccine hesitant><viral infection><viral pathogen><virus infection><virus pathogen><virus pathogenesis><virus-induced disease>